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Plasmacytoid DCs (pDCs) are bone marrow–
derived cells that specialize in the secretion of 
type I IFNs (IFN-I). pDCs detect RNA and 
DNA viruses through two endosomal sensors, 
toll-like receptor (TLR) 7 and TLR9, respec-
tively, which induce secretion of IFN-I through 
the MyD88–IRF7 signaling pathway (Gilliet   
et al., 2008). IFN-I confers resistance to viral in-
fections and promotes NK cell, DC, T cell, and 
B cell functions (García-Sastre and Biron, 2006). 
In addition to secreting IFN-I, pDCs pro-
duce IL-12, IL-6, and chemokines that con-
tribute to innate and adaptive immune responses 
(Trinchieri,  2010).  pDCs  also  express  major 
histocompatibility complex and costimulatory 
molecules, and therefore may directly partici-
pate in presentation and cross-presentation of 
antigens to T cells (Villadangos and Young, 
2008). Thus, pDCs have been implicated in both 
innate and adaptive immunity.
In  mice,  it  has  been  reported  that  pDC 
numbers decline in spleens after TLR7/9 stim-
ulation and during certain viral infections such 
as murine cytomegalovirus (MCMV) and lym-
phocytic  choriomeningitis  virus  (LCMV; 
Asselin-Paturel et al., 2005; Zuniga et al., 2008; 
Lee et al., 2009). Decreased numbers of circu-
lating pDCs have been observed in patients 
infected with Hepatitis B or C viruses (Duan 
et al., 2004; Kanto et al., 2004). pDC numbers 
are also reduced in the blood of patients in-
fected with HIV. Loss of pDCs correlates with 
high viral load, decreased CD4+ T cell counts, 
and the onset of opportunistic infections (Finke 
et al., 2004; Altfeld et al., 2011). At present, it 
is unclear what factors are responsible for the 
diminution of pDCs during human infections. 
pDCs could be direct targets of HIV because 
they  express  the  HIV  receptors  and/or  they 
may migrate into secondary lymphoid tissues 
where  they  undergo  apoptosis  by  yet  un-
defined mechanisms (Fonteneau et al., 2004; 
Malleret et al., 2008; Brown et al., 2009).
In this study, we investigated the turnover 
of pDCs in vivo during several systemic viral 
infections. We observed a marked reduction in 
splenic pDCs in infected mice, which inversely 
correlated with systemic levels of IFN-I. Viral 
infection induced the up-regulation of proapop-
totic molecules in pDCs in an IFN-I–dependent 
manner resulting in caspase activation and death. 
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Plasmacytoid dendritic cells (pDCs) specialize in the secretion of type I interferons (IFN-I) and 
thus are considered critical mediators of antiviral responses. We recently reported that pDCs 
have a very early but limited and transient capacity to curtail viral infections. Additionally, 
pDC numbers are not sustained in human infections caused by Hepatitis B or C viruses (HBV 
and HCV) and HIV. Thus, the numbers and/or function of pDCs appear to be regulated during 
the course of viral infection. In this study, we show that splenic pDCs are reduced in vivo 
during several systemic viral infections and after administration of synthetic toll-like recep-
tor ligands. We demonstrate that IFN-I, regardless of the source, contributes to this decline 
and mediates pDC death via the intrinsic apoptosis pathway. These findings demonstrate a 
feedback control mechanism by which IFN-I modulates pDC numbers, thus fine-tuning 
systemic IFN-I response to viruses. IFN-I–mediated control of pDCs may explain the loss of 
pDCs during human infections caused by HBV, HCV, or HIV and has important therapeutic 
implications for settings in which IFN-I is used to treat infections and autoimmune diseases.
© 2011 Swiecki et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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mainly located in the white pulp (Fig. 1 D). Consistent with 
flow cytometry data, we found a significant reduction in the 
number of pDCs in MCMV-infected mice (Fig. 1 D). Lack of 
pDCs was heterogeneous, with areas of white pulp almost com-
pletely devoid of Siglec-H+ cells (Fig. 1 D). The residual pDC 
population was occasionally found to form microclusters sur-
rounding the periarteriolar lymphoid sheets (unpublished data).
Interestingly, in mice lacking efficient NK cell responses 
to MCMV (129/SvJ), we observed increased levels of sys-
temic IFN- and a more profound reduction in pDC numbers 
compared with MCMV-infected C57BL/6 mice (Fig. 1 E). In-
fection with LCMV clone 13, which establishes a chronic 
infection in mice, caused a transient drop in splenic pDC 
numbers around the time when IFN- concentrations peak 
in the serum (Fig. 1 F), consistent with previous results 
(Zuniga et al., 2008; Lee et al., 2009). Our data suggests that 
pDC numbers plummet when IFN-I levels are prevalent in 
the serum and begin to recover when systemic IFN-I is no 
longer detectable. Thus, IFN-I might contribute to the rapid 
decline of pDCs during certain viral infections. In support of 
this, infection with vaccinia virus (VACV) did not elicit high 
levels of systemic IFN-I or cause a dramatic reduction in 
pDC numbers (Fig. 1 G).
IFN-I signaling induces pDC activation and death in vivo
To test whether the decline in pDC numbers during infection 
was related to pDC activation, death, and/or IFN-I signaling, 
we infected WT and IFNAR/ mice with HSV-1 and then 
assessed frequencies of splenic pDCs (CD11c+Siglec-H+) and 
their expression of PDC-TREM and caspase. PDC-TREM is 
an early activation marker expressed by pDCs that is induced 
These findings unveil a novel feedback control mechanism 
by which IFN-I modulates pDC numbers in vivo for pre-
venting excessive systemic IFN-I response to viruses.
RESULTS AND DISCUSSION
pDCs are reduced during systemic viral infections  
that induce IFN-I
To investigate the fate of pDCs during systemic viral infections, 
we infected C57BL/6 mice with disparate RNA or DNA vi-
ruses known to activate pDCs through the TLR7/9–MyD88–
IRF7 pathway and monitored pDC numbers (B220+Siglec-H+ 
or CD11c+Siglec-H+) and systemic IFN- levels at different 
time points post infection (p.i.). Flow cytometric analysis of 
spleens from HSV-1–infected mice revealed a decrease in pDCs 
compared with uninfected animals that was paralleled by an in-
crease in serum IFN- levels (Fig. 1 A). The reduced numbers 
of pDCs were not a result of the down-regulation of Siglec-H 
and therefore the inability to detect pDCs, as SiglecH-eGFP 
gene-targeted mice also had decreased numbers of GFP+ pDCs 
after infection with HSV-1 (unpublished data). HSV-1 infec-
tion in other mouse strains also led to reduced numbers of 
pDCs, suggesting that the decline of pDCs after systemic virus 
infection is not strain dependent (unpublished data).
Infection with vesicular stomatitis virus (VSV) expressing 
OVA (VSV-OVA) or MCMV also resulted in the reduction of 
splenic pDCs during the first few days of infection when 
IFN- levels were abundant in the serum (Fig. 1, B and C). 
To corroborate our flow cytometry data, we evaluated pDC 
numbers  in  spleens  by  histology.  Frozen  tissue  sections  of 
spleens obtained from control and MCMV-infected (36 h p.i.) 
mice stained with anti–Siglec-H showed numerous pDCs, 
Figure 1.  Decline of splenic pDCs during 
systemic viral infections. Mice were infected 
with RNA or DNA viruses and absolute num-
bers of pDCs and serum IFN- levels were 
determined at different time points p.i.  
(A) C57BL/6 mice were infected with 107 pfu 
HSV-1. Data are representative of two experi-
ments with four mice per time point.  
(B) C57BL/6 mice were infected with 5 × 106 
pfu VSV-OVA. Data are representative of two 
experiments with four mice per time point.  
(C) C57BL/6 mice were infected with 5 × 104 
pfu MCMV. Data are combined from two ex-
periments with five to six mice per time point. 
(D) Spleen sections from uninfected (Ctrl) and 
MCMV-infected C57BL/6 mice were stained 
for Siglec-H (blue) and CD3 (brown). A magni-
fication is shown in the inset. Bar, 100 µm. 
The graph shows mean pDC numbers per high 
power field (HPF) in Ctrl and MCMV-infected 
spleen sections (n = 8). (E) pDC numbers in 
spleens and serum IFN- levels were determined from C57BL/6 (5 × 104 pfu MCMV; 104 pfu m157) and 129/SvJ (104 pfu MCMV) mice infected or not 
for 48 h (n = 4–5 mice per group). (F) C57BL/6 mice were infected with 3 × 106 pfu LCMV clone 13. Data are combined from two experiments with six to 
eight mice per time point. (G) C57BL/6 mice were infected with 2 × 106 pfu VACV. Data are representative of two experiments with three to five mice per 
time point. (A–C and E–G) Error bars represent means ± SEM. (A, F, and G) pDC numbers, black bars; IFN- levels, white bars. (B and C) pDC numbers, 
open squares; IFN- levels, closed circles. (D) Statistical significance is indicated by **, P < 0.001. Error bars represent means ± SD.JEM Vol. 208, No. 12  2369
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of PDC-TREM or differences in caspase activation in pDCs 
from control and infected animals (Fig. 2 B).
Quantitative analysis of pDC numbers in control and 
HSV-1–infected mice revealed a greater reduction in WT 
mice compared with IFNAR/ mice (Fig. 2 C). Concomi-
tantly, when IFN-I signaling was blocked with anti-IFNAR 
mAb in WT mice before infection with HSV-1, pDC num-
bers and survival remained similar to those found in uninfected 
mice (Fig. 2 D). To validate that pDCs were in fact under-
going apoptosis in an IFN-I–dependent manner, we evaluated 
both caspase+ and Annexin V+ pDCs in WT and IFNAR/ 
by TLR and IFN-I signaling (Watarai et al., 2008), whereas 
caspase activation is indicative of apoptosis. In HSV-1– 
infected WT mice, the frequencies of pDCs fell more than two-
fold and those pDCs remaining expressed more PDC-TREM 
on the cell surface than pDCs from control mice (Fig. 2 A). 
Using a pan-caspase inhibitor that is an in situ marker for 
apoptosis, we found that 37% of pDCs from infected WT 
mice were caspase+ compared with 11% in uninfected mice. 
In IFNAR/ mice infected with HSV-1, the frequencies of 
splenic  pDCs  were  comparable  to  uninfected  IFNAR/ 
mice (0.4 and 0.5, respectively) and there was no up-regulation 
Figure 2.  pDCs undergo cell death during systemic HSV-1 infection in an IFN-I–dependent manner. (A and B) C57BL/6 (A) and IFNAR/  
(B) mice were infected with 107 pfu HSV-1 for 8 h. Control mice were uninfected. pDC frequencies in spleens, expression of PDC-TREM, and caspase acti-
vation in pDCs were measured by flow cytometry. Dot plots and histograms show data from three to five mice per genotype representative of three ex-
periments. (C) pDC numbers in spleens from C57BL/6 and IFNAR/ mice infected or not with 107 pfu HSV-1 for 8 h. Data are representative of three 
experiments with three to five mice per group. Percentages denote the reduction in pDC numbers in infected mice relative to controls. (D) C57BL/6 mice 
were treated with an isotype control mAb or anti-IFNAR mAb 4 h before infection with 107 pfu HSV-1. Bar graphs show absolute numbers of pDCs (left) 
and frequencies of caspase+ pDCs (right) in control and infected mice 8 h p.i. Data are representative of two experiments with three to four mice per 
group. Percentages indicate the reduction in pDC numbers in infected mice relative to controls. Statistical significance is indicated by ***, P < 0.0001.  
(E) C57BL/6 and IFNAR/ mice were infected or not with 107 pfu HSV-1 for 8 h. Caspase+ and Annexin V+ pDCs were determined by flow cytometry. Data 
are representative of two experiments with three to four mice per group. Statistical significance is indicated by ***, P ≤ 0.0006. (F) MyD88/ mice were 
infected or not with 107 pfu HSV-1. pDC frequencies in spleens, expression of PDC-TREM, and caspase activation in pDCs were measured by flow cytom-
etry 8 h p.i. Dot plots and histograms show data from three to five mice per group representative of two experiments. (G and H) Mice of the indicated 
genotype were infected or not with 107 pfu HSV-1 for 8 h. Bar graphs show frequencies of caspase+ pDCs in spleens (G) and serum IFN- levels (H). Data 
are combined from two experiments with four to eight mice per genotype. Statistical significance is indicated by **, P < 0.007; ***, P < 0.0007. (I) C57BL/6 
mice were infected or not with different doses of HSV-1 (107, 106 or 105 pfu) for 8 h. pDC numbers in spleens, serum IFN- levels, and Annexin V+ pDCs 
were determined. Data are from representative of two experiments with three to four mice per group. (C–E and G–I) Error bars represent means ± SEM.2370 Type I interferon mediates death of pDC | Swiecki et al.
Annexin V, were determined. The frequencies and numbers 
of  pDCs  declined  in  IFN-I–treated  WT  mice  but  not   
IFNAR/ mice (Fig. 3, D and E). Furthermore, we detected 
more caspase+ and Annexin V+ pDCs in WT mice treated 
with IFN-I compared with IFNAR/ mice (Fig. 3 E). 
Thus, our findings indicate that although pDCs can be a 
source of IFN-I that induces pDC death, additional sources 
of endogenous, as well as exogenous, IFN-I can regulate pDC 
numbers in vivo.
mice infected with HSV-1. Frequencies of caspase+ and 
Annexin V+ pDCs were significantly higher in infected WT 
mice compared with infected IFNAR/ mice (Fig. 2 E). Col-
lectively, these data show that pDC activation and death during 
systemic viral infection are dependent on IFN-I signaling.
To establish the impact of TLR signaling on pDC sur-
vival, we infected MyD88/ mice i.v. with HSV-1. Infected 
MyD88/ mice had an intermediate phenotype between 
that of infected WT and IFNAR/ mice (Fig. 2 F). pDC 
frequencies were partially reduced compared with uninfected 
controls but not to the extent observed in WT mice. Similarly, 
minor fractions of pDC from HSV-1–infected MyD88/ 
mice were caspase+ compared with uninfected mice and to 
pDCs from infected WT mice. In contrast to IFNAR/ 
pDCs, MyD88/ pDCs up-regulated PDC-TREM during 
HSV-1 infection. The differences in caspase activation ob-
served in pDCs from WT versus IFNAR/ and MyD88/ 
mice correlated with systemic IFN- levels. On average, the 
frequencies of caspase+ pDCs in WT mice approached 40%, 
compared with 14 and 20% in IFNAR/ and MyD88/ 
mice, respectively (Fig. 2 G). Following that trend, serum 
IFN-  levels  in  WT  mice  were  4.0  ng/ml,  whereas   
IFNAR/ and MyD88/ mice had levels of 0.3 and 
0.8 ng/ml, respectively (Fig. 2 H). Thus, during systemic 
HSV-1 infection, MyD88 signaling contributes in part to sys-
temic IFN- levels and pDC death but not to pDC activa-
tion as measured by PDC-TREM expression. Finally, we 
determined whether pDC survival was impacted by the dose 
of HSV-1 inoculum. As virus inoculum increased, pDC num-
bers declined, whereas serum IFN- levels and Annexin V+ 
pDCs increased (Fig. 2 I). These data indicate that pDC death 
correlates with viremia and systemic IFN- levels.
Sources of IFN-I that promote pDC death
Given that pDCs are a source of IFN-I during HSV-1 infec-
tion (Krug et al., 2004), we asked whether caspase activation 
in pDCs is dependent on pDC-derived IFN-I and/or alter-
native IFN-I sources. Studies in pDC-depleted mice (Swiecki 
et al., 2010) revealed that pDCs are a major source of IFN- 
early during HSV-1 infection but not at later time points 
(Fig. 3 A and not depicted), suggesting that pDCs produce 
the IFN-I that induces their death. To evaluate this, we looked 
at IFN- levels and caspase activation in mice injected with 
the synthetic ligands CpGA and polyinosinic:polycytidylic 
acid (poly(I:C)). CpGA elicits IFN-I in pDCs through TLR9, 
whereas poly(I:C) induces IFN-I production from cDC 
and/or macrophages and stromal cells via TLR3 and MDA5, 
respectively (Gilliet et al., 2008; Longhi et al., 2009). We 
found that depleting pDCs has an impact on IFN- produc-
tion  in  response  to  CpGA  but  not  poly(I:C)  (Fig.  3  B), 
whereas administration of either ligand resulted in pDC acti-
vation and death (Fig. 3 C).
We next asked whether the direct administration of IFN-I 
impacts pDC numbers in vivo. To test this, WT and IFNAR/ 
mice were injected with recombinant IFN- and IFN-5, 
and pDC numbers, as well as pDC expression of caspase and 
Figure 3.  IFN-I–mediated death of pDCs does not depend on the 
IFN-I source. (A) BDCA2-DTR Tg mice were injected with PBS or DT before 
107 pfu HSV-1. Serum IFN- levels were measured by ELISA 6 h p.i. Data 
are combined from two experiments with five mice per group. (B) BDCA2-
DTR Tg mice were injected with PBS or DT before CpGA or poly(I:C). Serum 
IFN- levels were determined by ELISA 8 h after CpGA or 8 and 24 h after 
poly(I:C). Data are representative of two experiments with four to five mice 
per group. (C) BDCA2-DTR Tg mice were injected with CpGA or poly(I:C) 
and pDC frequencies in spleens, expression of PDC-TREM, and caspase 
activation were measured by flow cytometry 8 h after CpGA or 16 h after 
poly(I:C) administration. Dot plots and histograms show data from three to 
four mice per group representative of two experiments. Statistical signifi-
cance is indicated by **, P < 0.008. (D and E) C57BL/6 and IFNAR/ mice 
were injected with recombinant mouse IFN-I. (D) Dot plots show frequen-
cies of pDCs in spleens 12 h after injection. (E) Absolute numbers of pDCs 
(left) as well as caspase+ and Annexin V+ pDCs in spleens (right) 12 h after 
injection. Data are representative of two experiments with three mice per 
group. Statistical significance is indicated by **, P < 0.006; ***, P ≤ 0.0008. 
(A, B, and E) Error bars represent means ± SEM.JEM Vol. 208, No. 12  2371
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pDC death occurs independently of the extrinsic  
apoptosis pathway
We next evaluated potential mechanisms leading to IFN-I–
dependent caspase induction in pDCs. IFN-I induces the ex-
pression of Fas and TNF-related apoptosis-inducing ligand 
(TRAIL) which, through Fas/FasL and TRAIL/death recep-
tor 5 (DR5) interactions, induce apoptosis via the extrinsic 
pathway. Using WT and IFNAR/ mice infected i.v. with 
HSV-1, we found that a fraction of pDCs from WT, but not 
IFNAR/, mice up-regulated Fas, whereas pDCs from both 
groups expressed very low levels of DR5 (Fig. 4 A). TRAIL 
and FasL were not clearly detectable on pDCs from any of 
the groups (unpublished data). FasL was detected at minimal 
levels on NK and NKT cells during HSV-1 infection (Fig. 4 B), 
which prompted us to examine whether caspase activation 
and pDC death might be mediated by Fas/FasL interactions 
with either NK or NKT cells. Disrupting Fas/FasL inter-
actions by Ab blockade did not impact IFN- responses to 
HSV-1 or prevent caspase activation in pDCs (Fig. 4 C).
Although we could not detect TRAIL on NK cells or 
pDCs, we attempted to block any potential TRAIL/DR5 
interactions in vivo with an anti-TRAIL mAb before infect-
ing mice with HSV-1. Blocking TRAIL had no impact on 
IFN- production or caspase activation in pDCs (Fig. 4 D). 
We also asked whether NK or NKT cells might kill pDCs via 
perforin/granzyme, which can be induced by IFN-I during 
virus infections (García-Sastre and Biron, 2006). Although 
NK and NKT cells up-regulated granzyme B during HSV-1 
infection (Fig. 4 E), depletion of NK1.1+ cells before HSV-1 
infection did not have an impact on pDC frequencies or cas-
pase activation (Fig. 4 F). Collectively, these data suggest that 
pDC death is independent of Fas/FasL or TRAIL/DR5 
interactions and NK or NKT cell cytolytic activity during 
HSV-1 infection.
Systemic HSV-1 infection induces pDC expression  
of proapoptotic molecules in an IFN-I–dependent manner
We next evaluated the expression of molecules involved in 
the intrinsic apoptosis pathway. The Bcl-2 family is composed 
of several proteins that exert either pro- or antiapoptotic func-
tions (Youle and Strasser, 2008). To ascertain whether IFN-I 
induced the expression of proapoptotic molecules in pDCs 
during  systemic  HSV-1  infection,  we  isolated  RNA  from 
pDCs  sorted  from  naive  and  HSV-1–infected  WT  and   
IFNAR/ mice and then measured transcripts for pro- and 
antiapoptotic molecules by quantitative (q) PCR (Fig. 4 G). 
Figure 4.  pDCs up-regulate extrinsic and intrinsic apoptotic pro-
teins in an IFN-I–dependent manner during systemic HSV-1 infec-
tion. (A–I) Mice were infected or not with 107 pfu HSV-1. (A) Expression of 
Fas and DR5 on pDCs from spleens was determined 8 h p.i. Histograms 
show data from three to five mice per group from two experiments.  
(B) FasL expression on NK, NKT, and T cells from spleens of control and 
HSV-1–infected C57BL/6 mice 8 h p.i. Histograms show data from three to 
five mice per group from three experiments. (C) C57BL/6 mice were 
treated or not with anti-FasL mAb before HSV-1 infection. Bar graphs 
show serum IFN- levels (left) and frequencies of caspase+ pDCs (right) in 
spleens 8 h p.i. (D) C57BL/6 mice were treated or not with anti-TRAIL mAb 
before HSV-1 infection. Bar graphs show serum IFN- levels (left) and 
frequencies of caspase+ pDCs (right) in spleens 8 h p.i. (E) Granzyme B 
(GrB) expression on NK, NKT, and T cells from spleens of control and HSV-1– 
infected C57BL/6 mice 8 h p.i. Histograms show data from three to five 
mice per group from two experiments. (F) Mice were depleted of NK1.1+ 
cells before HSV-1 infection. Dot plots show frequencies of pDCs and 
histograms show frequencies of caspase+ pDCs in spleens 8 h p.i. Data  
are representative of two experiments with four mice per group.  
(G and H) C57BL/6 and IFNAR/ mice were infected or not with HSV-1, 
RNA was isolated from pDCs sorted from spleens 4 h p.i., and relative levels 
of pro- and antiapoptotic molecules were measured in duplicate by qPCR.  
(G) Relative expression in naive (left) and HSV-1–infected (right) pDCs.  
(H) Fold change in WT and IFNAR/ mice. (I) Absolute numbers of pDCs in 
spleens were determined in C57BL/6, IFNAR/, and Bim/Bid/ mice 8 h 
p.i. The bar graph shows the percent reduction in pDCs in HSV-1–infected 
mice compared with controls. Data are combined from two experiments 
with four mice per group. Statistical significance is indicated by **, P < 
0.005. (C and D) Data are representative of two experiments with three to 
five mice per group. (G and H) Data are representative of two experiments 
where pDCs were sorted and pooled from three mice per genotype.  
(C, D, and G–I) Error bars represent means ± SEM.
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Lee et al., 2009). Current treatments for chronic Hepatitis C 
virus (HCV) infection include IFN- in combination with 
ribavirin. Interestingly, it has been reported that blood pDCs 
are reduced in HCV patients receiving IFN- therapy com-
pared with untreated patients (Goutagny et al., 2004). Our 
findings suggest that treatment with IFN-I may also nega-
tively regulate pDC numbers during human infections.
MATERIALS AND METHODS
Mice and treatments. All animal studies were approved by the Washington 
University Animal Studies Committee. IFNAR/ mice (C57BL/6 back-
ground) were provided by A. French (Washington University, St. Louis, 
MO). Bim/ and Bid/ mice have been previously described (Bouillet 
et al., 1999; Kaufmann et al., 2007) and were provided by A. Strasser (Walter 
and Eliza Hall Institute, Victoria, Australia). C57BL/6, BDCA2-DTR Tg 
and 129/SvJ were bred in house. Heterozygous SiglecH-eGFP gene- 
targeted mice on a 129/SvJ background have been recently described and 
were bred in house (Swiecki et al., 2010). MyD88/ mice (C57BL/6 back-
ground) were bred in house. All mice were used at 6–12 wk of age. Diph-
theria toxin (DT; Sigma-Aldrich) was injected i.p. into BDCA2-DTR Tg 
mice (100–120 ng/mouse) 24 h before HSV-1, CpGA, or poly(I:C) ad-
ministration. Approximately 200 µg PK136 mAb was injected i.p. 48 h   
before HSV-1 infection. Purified anti-FasL mAb (CD178, clone MFL3;   
BioLegend) or purified anti-TRAIL mAb (CD253, clone N2B2; BioLegend) 
were injected i.v. at 100 µg per mouse 20 h before HSV-1 infection. Anti-
IFNAR and isotype control mAbs were injected i.v. at 625 µg per mouse 4 h 
before HSV-1. Recombinant mouse IFN- and IFN-5 were gifts from D. 
Fremont (Washington University, St. Louis, MO). Mice were injected i.v. 
with 15,000 U of both IFN- and IFN-5.
In  vivo  infections  and  stimulations. Kos strain HSV-1, Smith strain 
MCMV, MCMV AT1.5 (m157), Indiana strain VSV-OVA, LCMV clone 13, 
and VACV were provided by D. Leib (Dartmouth College, Hanover, 
NH), W. Yokoyama (Washington University, St. Louis, MO), A. French 
(Washington University, St. Louis, MO), L. Lefrançois (University of Con-
necticut, Farmington, CT), R. Ahmed (Emory University, Atlanta, GA), and 
L.  Deng  (Sloan-Kettering,  New  York,  NY),  respectively.  Salivary  gland 
stocks of MCMV and AT1.5 were administered i.p. HSV-1, and VSV-OVA, 
LCMV clone 13, and VACV were injected i.v. Administered doses of viruses 
are described in the figure legends. 6–9 µg CpGA 2216 (Operon) complexed 
with 30 µl DOTAP (Roche) was injected i.v. in phosphate-buffered saline. 
Poly(I:C) (GE Healthcare) was injected i.v. at 200 µg per mouse.
Cell preparations. Spleens were minced and digested for 45 min at 37°C 
in RPMI 1640 with collagenase D (Sigma-Aldrich). Single cell suspensions 
of spleens were prepared by passage through nylon mesh cell strainers (BD). 
EDTA was only used in MACS buffer for cell enrichment before sorting. 
Red blood cells were lysed with RBC lysis buffer (Sigma-Aldrich). Serum 
was separated from whole blood in serum collection tubes and stored at 
20°C until analysis.
Antibodies, flow cytometry, and cell sorting. The following reagents 
were obtained from BD, eBioscience, or BioLegend. Fluorochrome labeled 
anti-SiglecH (551), anti-B220 (RA3-6B2), anti-CD11c (HL3), anti-Ly6C 
(AL-21), anti-CD3 (145-2C11), anti-NK1.1 (PK136), anti–Granzyme B 
(GB11),  anti-CD262  (DR5,  MD5-1),  anti-CD178  (FasL,  MFL3),  anti-
CD95 (Fas, clone 15A7), anti-CD253 (TRAIL, clone N2B2), and Strepta-
vidin. Anti–PDC-TREM (clone 162.7, rat IgG2a) was purified from ascites 
and biotinylated using the FluoReporter Minibiotin kit (Invitrogen). Fc re-
ceptors were blocked before surface staining with supernatant from HB-197 
cells (American Type Culture Collection). Propidium iodide was used to 
determine pDC frequencies and numbers during virus infections shown in 
Fig. 1. Propidium iodide was not used in caspase activation or Annexin V 
experiments. All flow cytometry was conducted on a dual laser FACSCalibur 
We found that pDCs from infected WT mice strongly up-
regulated Bid, Bim, Noxa, and Bax while down-regulating 
Bcl-xl and Bcl-2 compared with pDCs from naive WT mice 
(Fig. 4 H). In contrast, pDCs from infected IFNAR/ mice 
displayed little to no change in the expression of proapoptotic 
molecules compared with pDCs from naive IFNAR/ mice, 
although, they did increase their expression of Bcl-xl and de-
crease their expression of Bcl-2 (Fig. 4 H).
We then asked if pDCs from mice deficient for components 
of the intrinsic pathway were more resistant to apoptosis after 
HSV-1 infection. To test this, we infected WT, IFNAR/, 
and  Bim/Bid/  mice  with  HSV-1  and  determined  pDC 
numbers 8 h p.i. pDC numbers were reduced 60% in WT mice 
and 8% in IFNAR/ mice infected with HSV-1 (Fig. 4 I). In 
Bim/Bid/ mice, pDC numbers were reduced 35%, indicat-
ing that in the absence of these two proapoptotic proteins 
pDC numbers were partially maintained. These data demon-
strate that IFN-I generated during systemic HSV-1 infection 
induces the expression of proapoptotic molecules in pDCs 
leading to caspase activation and cell death. Deficiency in 
components of the intrinsic apoptosis pathway results in in-
creased survival of pDCs during systemic HSV-1 infection.
Concluding remarks
In this study, we found that pDCs are reduced in vivo during 
several systemic viral infections. Mechanistically, we observed 
that IFN-I, regardless of the source, mediates pDC death 
in vivo by inducing the expression of proapoptotic molecules 
and caspase activation in pDCs. Previous studies have dem-
onstrated that IFN-I signaling promotes the survival of mouse 
and human pDCs ex vivo, and activates pDCs and induces 
their migration in vivo (Kadowaki et al., 2000; Asselin-
Paturel et al., 2001, 2005). Thus, the distinct outcomes of 
IFN-I signaling on pDCs suggest that pDC responses to IFN-I 
are influenced by the microenvironment. It has been shown 
that IFN-I regulates turnover of classical DCs in vivo by in-
ducing the up-regulation of proapoptotic molecules and cas-
pase activation (Mattei et al., 2009; Yen and Ganea, 2009; 
Fuertes Marraco et al., 2011). Impairment in DC turnover 
leads to increased numbers of DCs, chronic lymphocyte acti-
vation, and manifestations of autoimmunity (Nopora and 
Brocker, 2002; Chen and Wang, 2010). Similarly, the rapid 
turnover of pDCs during an IFN-I response in vivo may pre-
vent excessive IFN-I–mediated cellular activation, immuno-
pathology, and perhaps autoimmunity.
Our findings may explain the loss of pDCs during viral 
infections such as HIV, in which protracted deletion of pDCs 
might contribute to immunodeficiency. pDC numbers are 
reduced in patients with HIV but can be partially restored after 
antiretroviral therapy (HAART; Finke et al., 2004). Thus, 
HAART may reduce viral burden and systemic IFN-I levels 
improving the survival of pDCs during HIV infection (Boasso 
and Shearer, 2008). HIV infection may also affect pDC function 
or induce pDC anergy independently of IFN-I signaling, similar 
to what has been observed in experimental models of chronic 
viral infection with LCMV clone 13 (Zuniga et al., 2008;   JEM Vol. 208, No. 12  2373
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